Please login to the form below

Not currently logged in
Email:
Password:

Q&A

This page shows the latest Q&A news and features for those working in and with pharma, biotech and healthcare.

Q&A: Avril Lee

Q&A: Avril Lee

Perfect for a rainy Sunday afternoon! Which person, living or dead, do you admire the most and why? ... What’s your golden rule/piece of advice for someone starting a career in healthcare comms?

Latest news

  • Q&A: Emily Spilko Q&A: Emily Spilko

    It all matters and makes a difference. What’s the worst thing about working in healthcare comms? ... What’s your golden rule/piece of advice for someone starting a career in healthcare comms?

  • Q&A: Louise Sharp Q&A: Louise Sharp

    I love a list! What’s the best thing about working in healthcare comms? ... It is a privilege to work in an industry that can impact so many people.

  • Q&A: Shairose Ebrahim Q&A: Shairose Ebrahim

    motion, it’s not only a humbling experience but it also fills me with pride. ... For a healthcare comms geek like me, it’s the ideal combination of fact and fiction!

  • Q&A: Sarah Mikhailov Q&A: Sarah Mikhailov

    What has been your career highlight to date? Working on a gene replacement therapy. ... The work can be so varied, so get experience across a range of activities.

  • Q&A: Caroline Gosling Q&A: Caroline Gosling

    Being given the chance to lead an organisational transformation in a pharma company. ... That moment of bravery/blind faith led to a whole new career direction.

More from news
Approximately 54 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Case study: 4 Sites – Navigating the course ahead Case study: 4 Sites – Navigating the course ahead

    the critical mass needed to help shift practice at a national level, rather than just in pockets. ... board. Delegates want more from a stand- alone, including follow-up education via self-led remote learning, both on- demand and with live Q&A from KOLs.

  • Rare disease trials Q&A Rare disease trials Q&A

    With 350 million people affected worldwide, rare diseases represent a major unmet medical need. ... The selection of appropriate endpoints is crucial to provide substantial evidence of the efficacy of a drug.

  • Gene therapy market access Q&A Gene therapy market access Q&A

    Could Europe steal a march on the US if it gets cell and gene market access right? ... And frankly, as a UK taxpayer, I’m glad that that’s the case.

  • The Orkambi row explained The Orkambi row explained

    Q&A and timeline. The Orkambi row still isn’t resolved. Who is to blame for this mess? ... accept such a public offer without exposing its price negotiations elsewhere in the world.

  • Immunotherapy combination trials Q&A Immunotherapy combination trials Q&A

    What factors should sponsors weigh up when planning a new IO trial in 2019 and beyond? ... as the enthusiasm and available resources to dedicate to a study, should be selected.

More from intelligence
Approximately 17 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 27 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....

Infographics